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syndrome (SJS) and toxic epidermal necrosis (TEN), follow-
ing the administration of anticonvulsant drugs, and 24 pa-
tients who had used anticonvulsant drugs but did not have 
hypersensitivity reactions (the control group) were included 
in this study. Peripheral blood mononuclear cells were iso-
lated. The cells were stimulated with the drugs, phytohem-
agglutinin as a mitogen and  Candida as an antigen (positive 
controls). Lymphocyte proliferation was measured using the 
BrdU proliferation assay kit (Roche, Germany). The stimula-
tion index was calculated as the mean ratio of the OD of stim-
ulated cells divided by the OD of unstimulated cells. The re-
sults in the case and control groups were compared.  Results: 
Of 24 patients in the test group, 14 (58.3%) had positive LTT 
results and 10 (41.7%) had negative results. Among patients 
in the control group, 1 (4.2%) had a positive LTT result and 
23 (95.8%) had negative results. Among the patients who 
had received carbamazepine and phenytoin, there was a sig-
nificant difference between the results of LTT in the case and 
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 Abstract 
 Background/Aim: Administration of the anticonvulsant 
drugs phenobarbital, phenytoin, carbamazepine and la-
motrigine can be associated with severe hypersensitivity re-
actions. The lymphocyte transformation test (LTT) is a meth-
od to determine which drug has caused the hypersensitivity 
reaction. This study was done to evaluate the results of LTT 
in patients with delayed hypersensitivity reactions following 
the administration of anticonvulsants.  Methods: Twenty-
four patients with hypersensitivity reactions, e.g. drug-in-
duced hypersensitivity syndrome/drug rash and eosinophil-
ia with systemic symptoms (DIHS/DRESS), Stevens-Johnson 
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control groups (p = 0.002 and p = 0.028, respectively). Al-
though patients receiving lamotrigine and phenobarbital 
had more positive LTT results in the case group than in the 
control group, these differences were not statistically signif-
icant. The sensitivity, specificity, positive predictive value 
and negative predictive value of LTT were 58.4, 95.8, 93.3 and 
69.9%, respectively.  Conclusions: Considering the signifi-
cant difference in LTT results between the case and control 
groups in patients receiving carbamazepine and phenytoin, 
and not observing such a difference in patients receiving 
phenobarbital and lamotrigine, LTT results are more valu-
able for the diagnosis of hypersensitivity reactions following 
the administration of carbamazepine and phenytoin. The 
LTT has good specificity but low sensitivity for the diagnosis 
of drug hypersensitivity reactions.  © 2016 S. Karger AG, Basel 
 Introduction 
 Hypersensitivity reactions to drugs can cause a variety 
of skin diseases like maculopapular, bullous and pustular 
eruptions. In recent years, increasing evidence indicates 
the important role of T cells in these drug-induced skin 
diseases  [1] . Immune reactions to small molecular com-
pounds, such as drugs, can cause a variety of diseases in-
volving the skin, liver, kidney and lungs. In many drug 
hypersensitivity reactions, drug-specific CD4+ and CD8+ 
T cells recognize drugs through their alpha/beta T-cell 
receptors in an MHC-dependent way  [2] . Drugs can 
stimulate T cells like haptens via binding to self-peptides 
or interact directly with certain T-cell receptors. The
activation of drug-specific T cells is generally thought to 
play an essential role in mediating adverse drug reactions 
such as Stevens-Johnson syndrome (SJS), toxic epidermal 
necrosis (TEN) and drug-induced hypersensitivity syn-
drome/drug rash and eosinophilia with systemic symp-
toms (DIHS/DRESS)  [3, 4] . The presence of cytotoxic 
drug-specific T cells also orchestrates inflammatory skin 
reactions through the release and induction of various 
cytokines (i.e. IL-5, IL-6, TNF-α and IFN-γ) and chemo-
kines (RANTES or IL-8). The increased expression of 
these mediators seems to contribute to the generation of 
tissue and blood eosinophilia, a hallmark of many drug-
induced allergic reactions. However, in acute generalized 
exanthematous pustulosis (a peculiar form of drug aller-
gy), neutrophils represent the predominant cell type 
within pustules, probably due to their recruitment by IL-
8-secreting drug-specific T cells and keratinocytes  [1] . In 
clinical settings, the patch test and lymphocyte transfor-
mation test (LTT) are often used for the diagnostic assess-
ment of drug-specific T-cell responses  [5–15] . Despite it 
being widely understood that false-negative LTT reactions 
are observed in the acute stage regardless of the type of 
drug, studies have shown that positive LTT reactions can 
be observed when tests are performed 5–8 weeks after the 
onset of the drug reaction  [16] . The aim of this study was 
to evaluate the results of LTT in patients with hypersensi-
tivity reactions following anticonvulsant drug (phenobar-
bital, phenytoin, carbamazepine and lamotrigine) usage.
 Methods 
 Twenty-four patients with hypersensitivity reactions following 
the administration of anticonvulsant drugs and 24 patients who 
had used anticonvulsant drugs but did not have hypersensitivity 
reactions (controls) were included in this study ( table 1 ).
 According to the clinical presentation, the adverse drug reac-
tions were divided into 3 groups: SJS/TEN (n = 11), DIHS/DRESS 
(n = 9) and maculopapular skin eruptions (n = 8). The clinical 
criteria used for the diagnosis of SJS were the presence of wide-
spread erythematous macules or flat atypical targets and detach-
ment of <10% of the body surface area and for TEN, the presence 
of widespread erythematous macules or flat atypical targets and 
detachment of >30% of the body surface area  [11] . The diagnostic 
criteria for DIHS/DRESS were a high fever, a widespread maculo-
papular and/or diffuse erythematous eruption, lymphadenopa-
thy, leukocytosis with atypical lymphocytosis and/or eosinophilia 
and liver dysfunction  [12–15] . The LTT was performed in the re-
covery stage, at least 6 weeks after SJS/TEN, DIHS/DRESS and 
skin rashes.
 Culture Medium and Chemicals 
 Culture medium consisted of of RPMI 1640 (Gibco, Germany) 
supplemented with 10% pooled heat-inactivated human blood 
type AB serum, HEPES buffer (25 m M ; Gibco, Germany) and  L -
glutamine (2 m M; Gibco).
 Lymphocyte Transformation Test
 The culprit drugs used for LTT were unmodified parent drug 
compounds that were dissolved in suitable solvents (RPMI 1640 
for phenobarbital and lamotrigine, distilled water for phenytoin 
and methanol alcohol for carbamazepine) and then sonicated. So-
lutions were filtered and stored at –20  °  C.
 Peripheral blood mononuclear cells were isolated from whole 
blood using Ficoll/Hypaque (Sigma-Aldrich, USA) gradient cen-
trifugation. The drug cytotoxic level was determined as the drug 
dose that can inhibit phytohemagglutinin (PHA)-induced lym-
phocyte proliferation (data not shown), and the suitable dose was 
defined as the dose that can induce the most proliferation  [9] . The 
titration of the drug doses to find the suitable dose for LTT is de-
picted in  figure 1 . 200 μl of cell suspensions (10 6 cells/ml) were 
added to each culture-plate well and the cells were stimulated with 
50 μg/ml of phenytoin, 100 μg/ml each of phenobarbital and car-
bamazepine and 25 μg/ml of lamotrigine. The cells were also stim-
ulated with PHA and  Candida antigen (as positive controls) in 
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separate wells. The negative control comprised the cells without 
any stimulation. The cultures were performed in triplicate and in-
cubated for 5 days in humidified 37   °   C incubator with 5% CO 2 . 
Lymphocyte proliferation was measured, using a BrdU prolifera-
tion assay kit (Roche, Germany). The stimulation index (SI) was 
calculated as the mean ratio of the OD of stimulated cells divided 
by the OD of unstimulated cells. An SI >2 was considered as posi-
tive.
 Results 
 Twenty-four patients (15 males and 9 females with a 
mean age of 13.66 ± 6.02 years) experiencing hypersensi-
tivity reactions following the administration of anticon-
vulsant drugs, and 24 patients (15 males and 9 females 
with a mean age of 11.14 ± 8.6 years) who had used anti-
convulsant drugs but not had hypersensitivity reactions, 
were included in this study, as the case and control groups, 
respectively. The clinical features and findings of these 
patients are summarized in  table 1 .
 All patients had a normal response to PHA and  Can-
dida antigen (data not shown). Out of 24 patients in the 
case group, 14 (58.3%) had positive LTT results and 10 
(41.7%) had negative test results. Among the patients in 
the control group, 1 (4.2%) had a positive LTT result and 
23 (95.8%) had negative results. Among the patients who 
had received carbamazepine, 3 had a positive LTT result 
and 1 had a negative LTT result in the case group, but all 
4 patients in the control group had a negative LTT result; 
this difference was statistically significant (p = 0.028). Of 
the patients with hypersensitivity reactions following 
phenytoin administration, 3 had a positive LTT result 
and 1 had a negative result, but all the patients in the con-
trol group had a negative result (p = 0.002). LTT results 
were not significantly different between patients with and 
without hypersensitivity reactions following phenobarbi-
tal and lamotrigine usage (data not shown).
 The mean ± SD duration between the first intake of the 
drug and the onset of drug reactions was 65 ± 50.7 h. The 
mean time interval between drug intake and the develop-
ment of a hypersensitivity reaction was 43.64 ± 7.10 h in 
the case group with positive LTT results and 81.23 ± 17.30 
h in the test group with negative test results. This differ-
ence was statistically significant (p = 0.016).
 Of 24 patients in the case group, 10 (41.6%) took phe-
nobarbital, 4 (16.6%) had used phenytoin, 4 (16.6%) took 
carbamazepine and 8 (33.3%) took lamotrigine. The inci-
dence of different types of drug reactions in patients using 
different drugs is shown in  table 2 . There was no signifi-
cant relationship between the drugs used and the type of 
drug reactions.
 Table 1.  Characteristics of the patients
Cases Controls
Mean age ± SD years 13.66 ± 6.02 11.14 ± 8.6
Sex (male/female) 15/9 15/9
Drug
Phenobarbital 10 9
Phenytoin 4 10
Carbamazepine 4 4
Lamotrigine 8 2
Type of drug reaction
SJS/TEN 11
DIHS/DRESS 9
Maculopapular eruptions 4
 Values denote numbers of patients, unless otherwise specified.
 Table 2.  Types of drug reaction in patients with different drug us-
age
SJS/TEN DIHS/DRESS Maculopapular 
eruptions
Phenobarbital 4 3 3
Phenytoin 3 1
Carbamazepine 2 2
Lamotrigine 3 4 1
0
10 25 50
Drug concentration (μg/ml)
100 250
1.5
3.0
4.5
6.0
SI
Phenobarbital Lamotrigine
Phenytoin Carbamazepine
 Fig. 1. Titration of drug doses to find the suitable dose for the LTT. 
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 The mean duration of drug use in the control group 
that had negative LTT results was 135.04 ± 30.45 weeks, 
and in patients who had positive LTT results was 12 
weeks. The differences between the duration of drug use 
and the LTT results were not statistically significant.
 The incidence of different drug reactions in patients 
with positive and negative LTT results is summarized in 
 table 3 . No significant relationship was observed between 
LTT results and the type of drug reaction.
 The mean ± SD of the interval between the onset of the 
drug reactions and the time of performing LTT in the case 
group that had positive LTT results was 18 ± 3.05 months, 
and in patients who had negative LTT results, it was 35.23 
± 7.52 months. The difference was statistically insignifi-
cant (p = 0.174).
 The sensitivity, specificity and positive and negative 
predictive values (PPV and NPV) were calculated. Four-
teen patients in the case group had a positive LTT result 
and 10 had a negative result; 23 in the control group had 
a negative LTT and 1 had a positive LTT. According to 
the results of this study, LTT has a general sensitivity of 
58.4% and specificity of 95.8% for determination of the 
drug that has caused drug hypersensitivity to anticonvul-
sants. LTT PPV for the diagnosis of drug hypersensitivity 
was 93.3% and its NPV was 69.9%.
 Discussion 
 One of the side effects of antiepileptic drugs is delayed 
hypersensitivity reactions. Anticonvulsant hypersensi-
tivity syndrome is uncommon, but is potentially danger-
ous and life-threatening. The most common drugs that 
cause these reactions are phenytoin, phenobarbital and 
carbamazepine  [17–20] , and the most important reac-
tions include TEN/SJS, DRESS and maculopapular erup-
tions that may lead to death  [20, 21] . Drug hypersensitiv-
ity is one of the major problems among children and 
adults who are hospitalized and take different medica-
tions  [22] . Early diagnosis of drug allergy syndrome and 
withdrawal of the culprit drug is helpful to prevent fatal 
results  [23] . 
 The most important and widely used tests for the di-
agnosis and choice of appropriate medications are the 
LTT and the skin patch test  [6, 8, 11–15, 24] . Activated T 
cells play an important role in drug reactions  [3, 4, 9, 22] . 
Kano et al.  [16]  showed that an SI  ≥ 1.80 can be regarded 
as positive, and Tang et al.  [25] showed that an SI  ≥ 2 can 
be regarded as positive. In this study, we regarded SI  ≥ 2 
as positive. Tang et al.  [25]  showed that the test should be 
performed during the recovery phase. In our study, LTT 
was done on all the patients at least 6 weeks after the last 
drug reaction.
 We found that the LTT results were significantly dif-
ferent in the case and control groups in the patients who 
had used carbamazepine and phenytoin. A prospective 
study of 22 patients by Hari et al.  [26]  showed similar 
findings, with the LTT being positive in 67% of drug-al-
lergic patients. In a cohort of carbamazepine-hypersensi-
tive patients and controls, Naisbitt et al.  [4] showed that 
the LTT was positive only in hypersensitive patients. The 
potential use of this test in a clinical situation requires 
further investigation. It might be helpful for the identifi-
cation of the culprit drug in a patient on multiple drugs.
 Considering significant differences between the case 
and control groups for patients receiving carbamazepine 
and phenytoin, and not observing such a difference in 
those receiving phenobarbital and lamotrigine, we con-
clude that the LTT results are more valuable for diagnosis 
of hypersensitivity following administration of carba-
mazepine and phenytoin.
 In the study by Gex-Collet et al.  [27] , it was shown that 
LTT was often positive even years after the allergic reac-
tion, indicating that the sensitization was persistent and 
detectable for a long time. The authors also stated that 
there was no significant relationship between the time in-
terval, i.e. how long after the hypersensitivity reaction was 
performed, and the test results, and that this test can in-
deed be used for some years to find the culprit drug. In 
this study, we also showed no significant relationship be-
tween the time interval between the drug reaction and 
performing LTT and the results of the test.
 In this study, 1 patient in the control group had a pos-
itive LTT result. Although several studies have reported 
that LTT can identify allergic subjects, nonallergic ex-
posed controls can also respond. In the research by Ny-
feler and Pichler  [9] ,  2 of the nonatopic controls with es-
 Table 3.  Relationship between LTT results and type of reaction
Reaction type Patients with 
negative tests
Patients with 
positive tests
SJS/TEN 4 (40) 7 (50)
DIHS/DRESS 4 (40) 5 (35.7)
Other 2 (20) 2 (14.3)
Total 10 (100) 14 (100)
 Values denote n (%).
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tablished tolerance to β-lactams had a positive LTT result 
for benzylpenicillin and amoxicillin, respectively. This 
feature cannot be clearly explained.
 The LTT has many advantages. This test is safe, it of-
fers the possibility of investigating multiple drugs at the 
same time and its sensitivity and specificity are reported 
as 60–70% and 100%, respectively, for anticonvulsant 
drugs  [4] . In a retrospective study derived from the clini-
cal history of 923 drug-allergic patients, the test was 
shown to have a sensitivity and specificity of 78% and 
85%, respectively  [9] . According to the results of our 
study, the LTT has a general sensitivity of 58.4% and spec-
ificity of 95.8% for determining which drug has caused 
the hypersensitivity to anticonvulsants.
 According to the results of different studies, including 
this one, the LTT has a high specificity but a limited sen-
sitivity. A recent publication by Srinoulprasert and Pich-
ler  [28]  showed that the depletion of regulatory T cells can 
enhance LTT sensitivity, without affecting specificity; 
this could be an important step toward the optimization 
of the LTT for the diagnosis of drug hypersensitivity reac-
tions.
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